Pharmaceutical products

Tender description

NHS framework for the NHS London Region, Branded Medicines — Tranche A, Annual Tranche — Cytokine Modulators and other products and Dolutegravir/Lamivudine. Offer reference number: CM/PHR/16/5516 CM/PHR/16/5516/01 — London Tranche A — 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5516/02 — London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5516/03 — NHS framework agreement for the supply of Dolutegravir/Lamivudine — North of England — 1 September 2020-28 February 2021, South of England — 1 September 2020-31 August 2021, Midlands and East — 1 September 2020-28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5516/01 — London Tranche A — 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. Products associated with the lots are listed on document No 5 of the invitation to offer. Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above. CM/PHR/16/5516/02 — London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. Products associated with the lots are listed on Document No 5 of the invitation to offer. Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above. CM/PHR/16/5516/03 — NHS Framework agreement for the supply of Dolutegravir/Lamivudine — North of England — 1 September 2020-28 February 2021, South of England — 1 September 2020-31 August 2021, Midlands and East — 1 September 2020-28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. Products associated with the lots are listed on document No 5 of the invitation to offer. Each individual national product code (NPC) pack description in each of the regions is deemed to be a separate product for the application of the award criteria. There is no restriction on the number of products that bidders can offer for or be awarded. The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above.